AJANTPHARM — Ajanta Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹334.26bn
- IN₹327.02bn
- IN₹42.09bn
- 99
- 13
- 70
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.37 | ||
| PEG Ratio (f) | 2.21 | ||
| EPS Growth (f) | 16.57% | ||
| Dividend Yield (f) | 0.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.09 | ||
| Price to Tang. Book | 9.12 | ||
| Price to Free Cashflow | 36.27 | ||
| Price to Sales | 7.38 | ||
| EV to EBITDA | 25.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 29.05% | ||
| Return on Equity | 25.08% | ||
| Operating Margin | 24.89% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 25,878.7 | 28,896.9 | 33,409.9 | 37,426.4 | 42,087.1 | 45,971.89 | 51,850.4 | 15.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +22.09 | +39.05 | +9.56 | -16.53 | +40.41 | +12.65 | +16.57 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Directors
- Mannalal Agrawal NEC (68)
- Madhusudan Agrawal VCH (60)
- Gaurang Shah CCO (46)
- Rajesh Agrawal MDR (39)
- Yogesh Agrawal MDR (43)
- Prabhakar Dalal NID (62)
- Anjana Grewal NID (62)
- Chandrakant Khetan NID (69)
- K. Viswanathan NID (69)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 31st, 1979
- Public Since
- June 5th, 2000
- No. of Shareholders
- 57,095
- No. of Employees
- 7,844
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 124,912,099
- Address
- Ajanta House,, Charkop, Kandivli West,, MUMBAI, 400067
- Web
- https://www.ajantapharma.com/
- Phone
- +91 2266061000
- Contact
- Gaurang Shah
- Auditors
- BSR & Co. LLP
Upcoming Events for AJANTPHARM
Q4 2025 Ajanta Pharma Ltd Earnings Call
Q1 2026 Ajanta Pharma Ltd Earnings Release
Q2 2026 Ajanta Pharma Ltd Earnings Release
Similar to AJANTPHARM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Ajanta Pharma share price?
As of Today at 19:09 UTC, shares in Ajanta Pharma are trading at IN₹2,676.00. This share price information is delayed by 15 minutes.
How has the Ajanta Pharma share price performed this year?
Shares in Ajanta Pharma last closed at IN₹2,676.00 and the price had moved by +25.05% over the past 365 days. In terms of relative price strength the Ajanta Pharma share price has outperformed the S&P BSE 100 Index by +17.8% over the past year.
What are the analyst and broker recommendations for Ajanta Pharma?
The overall consensus recommendation for Ajanta Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ajanta Pharma dividend yield?
The Ajanta Pharma dividend yield is 1.05% based on the trailing twelve month period.
Does Ajanta Pharma pay a dividend?
Last year, Ajanta Pharma paid a total dividend of IN₹28.00, and it currently has a trailing dividend yield of 1.05%. We do not have any data on when Ajanta Pharma is to next pay dividends.
When does Ajanta Pharma next pay dividends?
We do not have data on when Ajanta Pharma is to next pay dividends. The historic dividend yield on Ajanta Pharma shares is currently 1.05%.
How do I buy Ajanta Pharma shares?
To buy shares in Ajanta Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ajanta Pharma?
As of the previous close price of IN₹2,676.00, shares in Ajanta Pharma had a market capitalisation of IN₹334.26bn.
Where are Ajanta Pharma shares listed?
Here are the trading details for Ajanta Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: AJANTPHARM
What kind of share is Ajanta Pharma?
Based on an overall assessment of its quality, value and momentum Ajanta Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ajanta Pharma share price forecast for 2025?
The analyst consensus target price for shares in Ajanta Pharma is IN₹2,911.25. That is 8.79% above the last closing price of IN₹2,676.00.
Analysts covering Ajanta Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹73.19 for the next financial year.
Find out moreWhat is the trend in the Ajanta Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ajanta Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -7.97%.
As of the last closing price of IN₹2,676.00, shares in Ajanta Pharma were trading -6.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ajanta Pharma PE Ratio?
The Ajanta Pharma PE ratio based on its reported earnings over the past 12 months is 31.37. The shares last closed at IN₹2,676.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ajanta Pharma?
Ajanta Pharma's management team is headed by:
- Mannalal Agrawal - NEC
- Madhusudan Agrawal - VCH
- Gaurang Shah - CCO
- Rajesh Agrawal - MDR
- Yogesh Agrawal - MDR
- Prabhakar Dalal - NID
- Anjana Grewal - NID
- Chandrakant Khetan - NID
- K. Viswanathan - NID